MarketCap
Facebook
X
TelegramGamida Cell Ltd. EBITDA 2011-2026 | GMDA
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Gamida Cell Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -62.7 M | -46.1 M | -33.4 M | -19.3 M | -23.6 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -19.3 M | -62.7 M | -37 M |
Quarterly EBITDA Gamida Cell Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -23.1 M | -22.5 M | - | - | -15.1 M | -12.8 M | - | - | - | -10.8 M | - | - | - | -9.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -9.89 M | -23.1 M | -15.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
232 M | $ 22.57 | 0.04 % | $ 3.74 B |  USA |
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | USA |
 |
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | USA |
 |
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | USA |
 |
Akebia Therapeutics
AKBA
|
24.8 M | $ 1.41 | -1.4 % | $ 363 M | USA |
 |
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | France |
 |
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | USA |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | USA |
 |
BioNTech SE
BNTX
|
15.3 B | $ 91.98 | -0.11 % | $ 27.2 B | Germany |
 |
Aytu BioScience
AYTU
|
-2.45 M | $ 2.56 | -3.76 % | $ 16.1 M | USA |
 |
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | Britain |
 |
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.85 | -1.39 % | $ 9.26 B |  Australia |
 |
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | USA |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 20.87 | 2.3 % | $ 976 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.75 M | - | -2.5 % | $ 5.88 M | USA |
 |
Aquestive Therapeutics
AQST
|
-70.5 M | $ 4.17 | -0.24 % | $ 446 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 24.57 | -0.16 % | $ 3.13 B | USA |
 |
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-101 M | - | - | $ 3.45 B | USA |
 |
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cabaletta Bio
CABA
|
-171 M | $ 3.17 | 2.59 % | $ 319 M | USA |
 |
Codiak BioSciences
CDAK
|
-64.2 M | - | -55.98 % | $ 2.15 M | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Avid Bioservices
CDMO
|
-7.57 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 2.93 | -4.87 % | $ 6.38 B | Israel |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |
 |
Celldex Therapeutics
CLDX
|
-284 M | $ 33.62 | 3.73 % | $ 2.23 B | USA |
 |
Concert Pharmaceuticals
CNCE
|
-76 M | - | - | $ 401 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-21.6 M | $ 3.92 | 1.03 % | $ 264 B | Britain |
 |
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | USA |
 |
Celsion Corporation
CLSN
|
-14.4 M | - | -6.63 % | $ 13.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | USA |